IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...

Among Largest Rural Health Systems in the U.S. “I appreciate the commitment Axonics has made to innovate in this space,” said Kevin Benson, M.D., a urogynecologist at Sanford Health who also served as ...

IRVINE, Calif. & KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable ...

An Axonics sacral neuromodulation system sends electrical signals to nerves in the spinal cord to help regulate the bladder and bowels Device maker Axonics Inc. says its newest system designed to ...

The U.S. Food and Drug Administration (FDA) approved Axonics (NASDAQ:AXNX) fourth-generation rechargeable sacral neuromodulation system (SNM). SNM is a therapy to treat urinary incontinence. The ...

Axonics Modulation Technologies Inc. Chief Executive Ray Cohen is nothing if not confident about becoming the market leader in his urology device category, despite renewed competition from medtech ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20 ® ...

Axonics Inc AXNX reported a Q1 EPS loss of $(0.19), better than the consensus of $(0.29). Sales increased 46% Y/Y to $70.65 million, beating the consensus of $65.26 million. The company expects FY23 ...